Efficacy and Safety of Hetrombopag in the Treatment of Recombinant Human Thrombopoietin-resistant Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2024 Dec 4

PMID 39628651

Authors

Jing Ni

Jian Hong

Xinglin Liang

Jifei Dai

Zhangbiao Long

ChengXin Luan

Mingzhen Yang

Qingsheng Li

Affiliations

Soon will be listed here.

Abstract

Background: Thrombocytopenia after allogeneic hematopoietic cell transplantation is a challenging clinical problem. Recombinant human thrombopoietin (rhTPO) and thrombopoietin receptor agonists are increasingly used in posttransplant thrombocytopenia. However, the use of hetrombopag in patients with posttransplant thrombocytopenia, especially in patients with resistance to rhTPO, has not yet been reported.

Objectives: The present study aimed to investigate the efficacy and safety of hetrombopag in patients with rhTPO-resistant posttransplant thrombocytopenia.

Methods: This retrospective study included 21 patients with rhTPO-resistant posttransplant thrombocytopenia who received hetrombopag from August 2021 to July 2022. The primary endpoint was the overall response rate, including partial response and complete response (CR). We also evaluated the predictors of hetrombopag efficacy and adverse events.

Results: The overall response rate to hetrombopag was 81%, and the CR rate was 62%. The median time from hetrombopag initiation to response and CR were 16 and 31 days, respectively. Decreased megakaryocytes in bone marrow negatively correlated with CR to hetrombopag ( = .03). All the patients tolerated hetrombopag well without any significant increase in adverse events. At the last follow-up, 71% of responders had discontinued hetrombopag and sustained their best response.

Conclusion: Our results suggested that hetrombopag is an effective treatment option to promote platelet recovery in patients with posttransplant thrombocytopenia, even in patients resistant to rhTPO.

References

Mahat U, Rotz S, Hanna R . Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 26(3):e65-e73. DOI: 10.1016/j.bbmt.2019.12.003. View

Bruno B, Gooley T, Sullivan K, Davis C, Bensinger W, Storb R . Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(3):154-62. DOI: 10.1053/bbmt.2001.v7.pm11302549. View

Peng G, He G, Chang H, Gao S, Liu X, Chen T . A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy. Ther Adv Hematol. 2022; 13:20406207221085197. PMC: 8972928. DOI: 10.1177/20406207221085197. View

Zhang X, Fu H, Xu L, Liu D, Wang J, Liu K . Prolonged thrombocytopenia following allogeneic hematopoietic stem cell transplantation and its association with a reduction in ploidy and an immaturation of megakaryocytes. Biol Blood Marrow Transplant. 2010; 17(2):274-80. DOI: 10.1016/j.bbmt.2010.09.007. View

Yuan C, Boyd A, Nelson J, Patel R, Varela J, Goldstein S . Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 25(7):1320-1324. DOI: 10.1016/j.bbmt.2019.01.027. View

Kuter D . Biology and chemistry of thrombopoietic agents. Semin Hematol. 2010; 47(3):243-8. PMC: 2904343. DOI: 10.1053/j.seminhematol.2010.02.005. View

Rivera D, Bastida J, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A . Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2018; 54(5):757-761. DOI: 10.1038/s41409-018-0368-1. View

Yao Y, Tang Y, Qi J, Li X, Zhang R, Xu X . Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review. Expert Rev Hematol. 2021; 14(11):1041-1048. DOI: 10.1080/17474086.2021.2009337. View

Jing F, Zhang X, Meng F, Liu X, Shi Y, Qin P . Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO. Thromb Res. 2018; 170:200-206. DOI: 10.1016/j.thromres.2018.08.021. View

10.

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S . Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(5):919-24. DOI: 10.1016/j.bbmt.2016.01.018. View

11.

Makar R, Zhukov O, Sahud M, Kuter D . Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol. 2013; 88(12):1041-4. DOI: 10.1002/ajh.23562. View

12.

Sun Y, Kong Y, Zhang X, Wang Y, Shi M, Song Y . A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. Platelets. 2018; 30(8):994-1000. DOI: 10.1080/09537104.2018.1557613. View

13.

Yamazaki R, Kuwana M, Mori T, Okazaki Y, Kawakami Y, Ikeda Y . Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. Bone Marrow Transplant. 2006; 38(5):377-84. DOI: 10.1038/sj.bmt.1705444. View

14.

Cao Y, Wang M, Shen B, Zhao F, Zhang R, Chen X . Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT. Clin Appl Thromb Hemost. 2022; 28:10760296211068037. PMC: 8761877. DOI: 10.1177/10760296211068037. View

15.

Mei H, Xu M, Yuan G, Zhu F, Guo J, Huang R . A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients. Br J Haematol. 2021; 195(5):781-789. DOI: 10.1111/bjh.17808. View

16.

Bao W, Bussel J, Heck S, He W, Karpoff M, Boulad N . Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010; 116(22):4639-45. PMC: 2996119. DOI: 10.1182/blood-2010-04-281717. View

17.

Liu X, Liu S, Feng Q, Liu X, Li G, Sheng Z . Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP. Blood. 2016; 128(6):852-61. DOI: 10.1182/blood-2016-01-690727. View

18.

Kuter D, Begley C . Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002; 100(10):3457-69. DOI: 10.1182/blood.V100.10.3457. View

19.

Yan F, Lu N, Gu Z, Huang W, Wang S, Gao X . Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience. Ann Hematol. 2021; 101(2):397-408. DOI: 10.1007/s00277-021-04706-6. View

20.

Syed Y . Hetrombopag: First Approval. Drugs. 2021; 81(13):1581-1585. DOI: 10.1007/s40265-021-01575-1. View